CN106459006B - 2,2,2-三氟乙基-噻二嗪 - Google Patents

2,2,2-三氟乙基-噻二嗪 Download PDF

Info

Publication number
CN106459006B
CN106459006B CN201580032183.8A CN201580032183A CN106459006B CN 106459006 B CN106459006 B CN 106459006B CN 201580032183 A CN201580032183 A CN 201580032183A CN 106459006 B CN106459006 B CN 106459006B
Authority
CN
China
Prior art keywords
thiadiazin
oxo
fluoropyridin
amino
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580032183.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459006A (zh
Inventor
莉莉·安塞尔姆
比约恩·巴特尔斯
科西莫·多伦特
沃尔夫冈·古帕
沃尔夫冈·哈普
延斯-乌韦·彼得斯
托马斯·沃尔特林
乌尔丽克·奥布斯特·森德
马克·罗杰斯-埃文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106459006A publication Critical patent/CN106459006A/zh
Application granted granted Critical
Publication of CN106459006B publication Critical patent/CN106459006B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580032183.8A 2014-08-15 2015-08-12 2,2,2-三氟乙基-噻二嗪 Expired - Fee Related CN106459006B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14181123 2014-08-15
EP14181123.2 2014-08-15
PCT/EP2015/068506 WO2016023927A1 (en) 2014-08-15 2015-08-12 2,2,2-trifluoroethyl-thiadiazines

Publications (2)

Publication Number Publication Date
CN106459006A CN106459006A (zh) 2017-02-22
CN106459006B true CN106459006B (zh) 2020-02-11

Family

ID=51302940

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580032183.8A Expired - Fee Related CN106459006B (zh) 2014-08-15 2015-08-12 2,2,2-三氟乙基-噻二嗪

Country Status (10)

Country Link
US (1) US9896438B2 (https=)
EP (1) EP3180330B1 (https=)
JP (1) JP6543697B2 (https=)
KR (1) KR20170043581A (https=)
CN (1) CN106459006B (https=)
BR (1) BR112016026814A8 (https=)
CA (1) CA2952160A1 (https=)
MX (1) MX375329B (https=)
RU (1) RU2692102C2 (https=)
WO (1) WO2016023927A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109180672A (zh) * 2018-09-29 2019-01-11 广东东阳光药业有限公司 亚氨基噻二嗪二氧化物衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044184A1 (en) * 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044181A1 (en) * 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN105683199A (zh) * 2013-12-20 2016-06-15 豪夫迈·罗氏有限公司 5-芳基-1-亚氨基-1-氧代-[1,2,4]噻二嗪

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19500558A1 (de) * 1995-01-11 1996-07-18 Merck Patent Gmbh 3-Alkoxycarbonyl-thiadiazinone
WO2014150331A1 (en) * 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
US9428476B2 (en) * 2013-03-15 2016-08-30 Merck Sharp & Dohme Corp. S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044184A1 (en) * 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044181A1 (en) * 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN105683199A (zh) * 2013-12-20 2016-06-15 豪夫迈·罗氏有限公司 5-芳基-1-亚氨基-1-氧代-[1,2,4]噻二嗪

Also Published As

Publication number Publication date
JP6543697B2 (ja) 2019-07-10
US20170226091A1 (en) 2017-08-10
EP3180330B1 (en) 2021-03-03
CA2952160A1 (en) 2016-02-18
MX2016016061A (es) 2017-03-10
BR112016026814A2 (pt) 2017-08-15
WO2016023927A1 (en) 2016-02-18
BR112016026814A8 (pt) 2021-07-20
MX375329B (es) 2025-03-06
KR20170043581A (ko) 2017-04-21
CN106459006A (zh) 2017-02-22
EP3180330A1 (en) 2017-06-21
US9896438B2 (en) 2018-02-20
RU2017107495A3 (https=) 2019-02-25
RU2017107495A (ru) 2018-09-17
RU2692102C2 (ru) 2019-06-21
JP2017524006A (ja) 2017-08-24

Similar Documents

Publication Publication Date Title
JP6681451B2 (ja) Ｂａｃｅ１阻害剤
CN104968660A (zh) 作为bace1抑制剂的氟-[1,3]噁嗪类化合物
CA2972098A1 (en) Selective bace1 inhibitors
CN103827110A (zh) 作为BACE1抑制剂的N-(3-(2-氨基-6,6-二氟-4,4a,5,6,7,7a-六氢-环戊二烯并[e][1,3]噁嗪-4-基)-苯基)-酰胺
US10829500B2 (en) Pyridyl-triazabicycles
CN105683199B (zh) 5-芳基-1-亚氨基-1-氧代-[1，2，4]噻二嗪
CN106459006B (zh) 2,2,2-三氟乙基-噻二嗪
CN107108652A (zh) Bace1抑制剂
CN107406440A (zh) Bace1抑制剂
HK1230195B (zh) 2，2，2-三氟乙基-噻二嗪
HK1230195A1 (en) 2,2,2-trifluoroethyl-thiadiazines
HK1232868B (zh) 吡啶基-三氮杂二环类化合物
HK1232868A1 (en) Pyridyl-triazabicycles
HK1216533B (zh) Bace1抑制剂
HK1244790B (zh) Bace1抑制剂
HK1238238B (zh) Bace1抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230195

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200211

CF01 Termination of patent right due to non-payment of annual fee